Revenue, 2025

USD 3.2 Bilion

Forecast, 2035

USD 25.36 Billion

CAGR, 2026-2035

23%

Report Coverage

Global

Targeted Protein Degradation Therapy Market Trends for 2026

The global targeted protein degradation therapy market size was estimated at USD 3.2 billion in 2025 and is predicted to increase from USD 3.94 billion in 2026 to approximately USD 25.36 billion by 2035, expanding at a CAGR of 23% from 2026 to 2035. The market is growing rapidly and expanding due to increasing focus on precision medicine and the development of innovative therapies for cancer, neurology, and rare diseases. Growing advancements in PROTACs and molecular glue technologies, along with rising biopharmaceutical investments, are further driving global market growth.

Key Takeaways

• Targeted protein degradation therapy market to crossed USD 3.94 billion by 2026.
• Market projected at USD 25.36 billion by 2035.
• CAGR of 23% expected in between 2026 to 2035.
• North America dominated the targeted protein degradation therapy market with a share of 40% in 2025.
• Asia Pacific captured 20% share in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.
• By technology, the proteolysis targeting chimeras (PROTACs) segment held a dominant position in the market with a share of 55% in 2025.
• By technology, the molecular glues segment held 15% share in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.
• By target disease, the cancer segment led the market with a share of 40% in the market in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.
• By drug class, the small molecules segment led the global targeted protein degradation therapy market with a share of 60% in 2025.
• By drug class, the biologics segment captured 40% share in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.
• By application, the therapeutic applications segment registered its dominance over the global market with a share of 75% in 2025, and is expected to grow at the fastest CAGR in the market during the forecast period.

Rising Demand for Next-Generation Precision Therapies

Targeted protein degradation is an advanced therapeutic approach that removes disease-causing proteins from cells using specialized molecules, helping treat conditions that are difficult to address with traditional drugs. The targeted protein degradation market is growing rapidly due to increasing demand for advanced therapies that can eliminate disease-causing proteins linked to cancer, neurological, and rare disorders. Innovations in PROTAC and molecular glue technologies, rising investments in drug discovery, and the ability to target previously untreatable in drug discovery, and the ability to target previously untreatable proteins are further accelerating market expansion across the global pharmaceutical and biotechnology sectors.

How Can AI Affect the Targeted Protein Degradation Market?

Artificial intelligence is transforming the market by accelerating drug discovery, predicting protein interactions, and improving the design of PROTACs and molecular glue therapies. AI-driven platforms help researchers identify effective degradation targets faster, reduce development timelines, and enhance clinical success rates. Growing adoption of AI in precision medicine and biotechnology research is expected to significantly boost innovation and market growth in the coming years.

Trend and Future Outlook of the Targeted Protein Degradation Market?

• Expansion of Clinical Trials: The number of clinical trials for targeted protein degradation therapies is increasing rapidly, especially in oncology and rare diseases. Growing success in early-stage studies is encouraging pharmaceutical companies to accelerate product development and commercialization efforts worldwide.
• Rising Focus on Undruggable Targets: Targeted protein degradation technologies are gaining attention for their ability to eliminate proteins that traditional drugs cannot effectively treat. This capability is expected to open new opportunities in cancer, neurological, and autoimmune disease treatment markets.
• Increasing Pharmaceutical Collaborations: Biotechnology firms and pharmaceutical companies are actively forming strategic partnerships to strengthen research, technology development, and drug pipelines. These collaborations are expected to support innovation, expand therapeutic applications, and drive long-term market growth globally.

Key Indicators and Highlights

Segmental Insights

By Technology Insights

The Proteolysis Targeting Chimeras (PROTACs) Segment Led in 2025

The proteolysis targeting chimeras (PROTACs) segment dominated the targeted protein degradation therapy market with a share of approximately 55% in 2025 due to its advanced clinical maturity and broad applicability across multiple disease targets. PROTAC technology enables selective and sustained degradation of pathogenic proteins, offering advantages over traditional inhibitors. Strong oncology pipelines, increasing clinical trial activity, favorable efficacy data, and growing pharmaceutical partnerships further strengthened PROTAC’s leading market position.

The autophagy-based degradation segment captured 20% share in 2025 due to increasing research into targeted protein clearance, rising investments in cellular therapy platforms, and growing interest in neurodegenerative disease treatment. Pharmaceutical companies expanded development programs focused on selective degradation pathways, while academic institutions strengthened collaborations for drug discovery. Improved understanding of mechanisms and funding opportunities further supported segment expansion.

The molecular glues segment held 15% share and is expected to grow at the fastest rate due to its simpler molecular structure, improved cell permeability, and oral bioavailability compared to PROTACs. Molecular glues can modulate protein-protein interactions using smaller compounds, enabling cost-effective development. Increasing research interest, expanding therapeutic potential, and successful clinical validation are accelerating adoption across oncology and immune-related diseases.

By Target Disease Insights

The Cancer Segment Dominated the Targeted Protein Degradation Therapy Market in 2025?

The cancer segment dominated the market with a revenue share of 40% in 2025, and is expected to be the fastest-growing segment during the forecast period due to the high prevalence of cancer and strong demand for targeted treatments. Protein degradation technologies effectively eliminate oncogenic proteins that are resistant to conventional therapies. Extensive oncology-focused clinical pipelines, increased investment in cancer research, and faster regulatory pathways for oncology drugs further reinforced this segments market leadership.

The neurodegenerative diseases segment held 30% share of the targeted protein degradation therapy market in 2025 as protein degradation therapies offer a novel way to remove toxic and misfolded proteins linked to neurodegenerative diseases. Rising prevalence of Alzheimer’s and Parkinson’s improved brain-penetrant molecules, increasing R&D focus, and growing unmet medical needs are driving rapid adoption and accelerating pipeline development in this therapeutic area.

The autoimmune diseases segment held 15% share in 2025 due to the rising prevalence of chronic immune disorders, growing adoption of precision therapies, and increased clinical research activities worldwide. Biopharmaceutical companies focused on developing immunomodulatory treatments with improved safety profiles and effectiveness. Government support for disease research, expanding diagnostic capabilities, and stronger patient awareness programs also contributed significantly to market demand.

The infectious diseases segment held 10% share in 2025 due to increasing concerns regarding antimicrobial resistance, rising investment in antiviral therapies, and efforts to improve pandemic preparedness. Research organizations and pharmaceutical companies accelerated the development of treatment platforms addressing bacterial, viral, and fungal infections. Expanding vaccination programs, healthcare infrastructure, and regulatory initiatives further strengthened market growth opportunities across emerging and developed markets.

Drug Class Insights

The Small Molecules Segment Led in 2025

The small molecules segment captured 60% share of the targeted protein degradation therapy market in 2025. Growth was supported by use in targeted therapies, easier manufacturing processes, and clinical success rates across disease areas. Pharmaceutical companies prioritized small-molecule development because of cost efficiency, oral administration advantages, and regulatory pathways. Expanding oncology research, increasing investments in drug discovery, and growing commercialization activities further reinforced segment leadership worldwide.

The biologics segment 40% share in 2025 and is expected to be the fastest-growing during the forecast period because of demand for medicine, adoption of monoclonal antibodies, and applications in rare diseases. Biotechnology companies strengthened investments in biologic manufacturing technologies and therapies. Improved treatment outcomes, regulatory approvals, and collaborations between firms and research organizations are expected to accelerate expansion.

Application Insights

The Therapeutic Application Segment Led the Market in 2025

The therapeutic applications segment captured 25% share of the targeted protein degradation therapy market and is expected to be the fastest-growing segment during the forecast period due to the use of therapies, clinical trials, and demand for treatment approaches across chronic diseases. Pharmaceutical companies focused on developing therapeutic solutions with effectiveness and safety profiles. Rising healthcare expenditure, reimbursement policies, and advancements in biotechnology research are expected to strengthen the segment.

The research applications segment captured 25% share in 2025. Growth was driven by academic research activities, funding for cellular pathway studies, and collaborations between biotechnology companies and research institutes. Scientists focused on understanding mechanisms, biomarker identification, and target validation through laboratory technologies. Improved availability of research grants, analytical tools, and broader adoption of precision medicine approaches further supported segment development.

Regional Insights

North America Leads Through Strong Innovation and Drug Development

North America dominated the targeted protein degradation market with a share of 40% in 2025 due to the presence of leading pharmaceutical and biotechnology companies, advanced healthcare infrastructure, and strong investment in innovative drug discovery. The region also benefits from increasing clinical trials, rising adoption of precision medicine, and growing research on PROTAC and molecular glue therapies. Additionally, supportive regulatory frameworks and high healthcare spending further strengthened regional market growth.

U.S. Market Trends

The U.S. targeted protein degradation market is leading due to the strong presence of major biotechnology and pharmaceutical companies, high research and development spending, and rapid adoption of advanced therapeutic technologies. Increasing clinical trials for PROTAC and molecular glue therapies, growing focus in precision medicine, and rising investments in oncology and neurological disease treatment are further supporting market leadership across the country.

Asia Pacific Emerges as the Fastest-Growing Regional Market

Asia Pacific held 20% share and is expected to grow at the fastest CAGR in the targeted protein degradation market due to increasing biotechnology investments, expanding pharmaceutical research activities, and rising demand for advanced precision therapies. Growing healthcare infrastructure, increasing prevalence of cancer and neurological disorders, and supportive government initiatives for drug innovation are further accelerating regional market growth. Additionally, expanding clinical trials and collaborations are strengthening market opportunities across the region.

India Market Trends

India is anticipated to grow at the fastest CAGR in the targeted protein degradation market due to rising investments in biotechnology research, expanding pharmaceutical manufacturing capabilities, and increasing focus on precision medicine. The growing prevalence of cancer and chronic diseases, supportive government initiatives for drug development, and increasing participation in clinical trials are further driving market growth. Additionally, the presence of cost-effective research infrastructure is boosting innovation opportunities.

Supply Chain Analysis

Clinical Trials

• Targeted Protein Degradation (TPD) is emerging as a fast-growing therapeutic area, with more than 40 drug candidates currently under clinical development, primarily for cancer treatment applications such as breast cancer, prostate cancer, and blood-related malignancies. The market is gaining strong attention due to increasing advancements in PROTAC technology and rising investments in precision medicine.
• Key players: Arvinas, C4 Therapeutics, Kymera Therapeutics, and Nurix Therapeutics.

Distribution to Hospitals, Pharmacies

• Targeted protein degradation therapeutics are gradually moving from clinical research stages toward commercial availability, increasing their presence across hospital and retail pharmacy channels. Growing demand for advanced precision therapies and expanding approvals for innovative degradation-based drugs are supporting market expansion.
• Key players: Bristol Myers Squibb, Pfizer, Amgen, and Monte Rosa Therapeutics

Patient Support and Services

• Patient support and service activities in the targeted protein degradation market are mainly centered on clinical development, research assistance, and therapy accessibility for cancer, neurological, and other difficult-to-treat diseases. As TPD therapies continue to advance, companies are increasingly focusing on improving patient access, clinical trial support, and treatment development processes to accelerate commercialization.
• Key players: Boehringer Ingelheim, Genentech, Foghorn Therapeutics, and Captor Therapeutics.

Top Vendors in the Targeted Protein Degradation Market & Their Offerings

SWOT Analysis

Strengths

• Targeted protein degradation technologies can remove harmful proteins that traditional drugs often cannot treat effectively.
• Growing demand for precision medicine is increasing interest in advanced degradation-based therapies.
• Strong research support and rising investments are accelerating innovation in PROTAC and molecular glue development.
• Expanding applications in cancer and neurological disorders are strengthening market growth potential.

Weaknesses

• Drug discovery and clinical development processes require significant time and financial investment.
• Limited number of approved therapies creates commercialization challenges for companies.
• Complex biological mechanisms can increase difficulties in safety evaluation and manufacturing.
• Lack of long-term clinical evidence may slow broader adoption in healthcare systems.

Opportunities

• Increasing focus on treating rare and previously untreatable diseases can create new growth opportunities.
• Expanding collaborations between pharmaceutical and biotechnology companies may accelerate innovation.
• Rising healthcare spending and advancements in personalized medicine are supporting market expansion.
• Growing research activities in autoimmune and infectious diseases may broaden therapeutic applications.

Threats

• Strict regulatory requirements may delay product approvals and market entry.
• High competition among biotechnology companies can affect profitability and market positioning.
• Clinical trial failures and safety concerns may impact investor confidence.
• Patent disputes and intellectual property challenges could restrict technology development and commercialization.

What are the Recent Developments in the Targeted Protein Degradation Market?

• In April 2024, Novartis strengthened its targeted protein degradation portfolio by acquiring VVD-101, a late-stage protein degrader candidate from Vividion Therapeutics for prostate cancer treatment. The therapy is designed to target the androgen receptor associated with cancer progression, supporting Novartis’ focus on advancing innovative oncology therapies and expanding its clinical development pipeline.
• In March 2024, C4 Therapeutics entered into a strategic research collaboration with Merck KGaA, Darmstadt, Germany, to advance targeted protein degradation therapies for oncology applications. The partnership focuses on utilizing C4 Therapeutics’ Degronimid platform to develop innovative small-molecule degraders aimed at critical cancer-related proteins, strengthening research and drug discovery efforts in the market.

Segments Covered in the Report

By Technology

• Proteolysis Targeting Chimeras (PROTACs)
• Autophagy-based Degradation
• Molecular Glues
• Other Technologies

By Target Disease

• Cancer
  • Solid Tumors
  • Hematological Malignancies
• Neurodegenerative Diseases
  • Alzheimer’s Disease
  • Parkinson’s Disease
• Autoimmune Diseases
• Infectious Diseases
• Others

By Drug Class

• Small Molecules
• Biologics

By Application

• Therapeutic Applications
  • Oncology
  • Neurology
  • Immunology
  • Other Therapeutic Areas
• Research Application
  • Drug Discovery
  • Cell Biology Research

By Region

• North America
  • U.S.
  • Canada
  • Mexico
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe
  • Western Europe
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe
    • Austria
    • Russia & Belarus
    • Türkiye
    • Albania
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA
  • GCC Countries
    • Saudi Arabia
    • United Arab Emirates (UAE)
    • Qatar
    • Kuwait
    • Oman
    • Bahrain
  • South Africa
  • Egypt
  • Rest of MEA